Abstracts from the 1st Immunotherapy of Cancer Conference (ITOC1)
- Poster presentation
- Open Access
P66. Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy
Journal for ImmunoTherapy of Cancer volume 2, Article number: P40 (2014)
The Wilms tumour antigen 1 (WT1) is a self-antigen expressed at high levels in leukaemic cells, but not in healthy tissue. WT1, therefore, is a favourable target antigen for allogeneic T cell therapy to prevent leukaemic relapse after stem cell transplantation. However, a comprehensive characterisation of CD4+ and CD8+ WT1-specific T cells is missing and the efficient expansion of a polyclonal WT1-reactive T cell population for clinical use has remained a major challenge.
In this study we aim to directly ex vivo characterize WT1-specific T cells present in the blood of healthy donors at high-resolution and to develop a method for the rapid generation of functionally potent, polyclonal CD4+ and CD8+ WT1-specific T cells for clinical use.
We utilise the magnetic enrichment of activation marker expressing cells after antigen-specific stimulation, as low frequencies of WT1-specific T cells in healthy donors do not allow direct detection.
Ex vivo frequencies of WT1-specific T cells range between 10-6 and 10-5 WT1-specific T cells within CD4+ T cells. In about 80% of healthy donors (n=15) a CD4+ memory response, accompanied by production of effector cytokines like IFN-γ and TNF-α against WT1 peptides is present. In contrast, detected CD137+CD8+ WT1-reactive T cells exhibit a naïve phenotype (CD45RA+CCR7+) in all tested donors (n=5).
An improved short-term expansion protocol to generate potent WT1-specific T cell cultures for clinical use was established utilising a CD137+ cell enrichment step. Notably, a high frequency of expanded CD4+ and CD8+ T cells show specific reactivity against WT1-presenting autologous cells as detected by production of effector cytokines after antigen-specific restimulation. Cytotoxic activity against antigen-loaded target cells could be shown by direct flow-cytometry-based cytotoxicity assays and antigen-specific upregulation of the degranulation marker CD107a. WT1-MHCI-Tetramerstainings furthermore confirmed antigen-specificity and suggested polyclonality within the CD8+ T cell population. In contrast to previous expansion protocols our polyclonally expanded T cells exhibit a favourable, unexhausted memory phenotype, express co-stimulatory markers CD27 and CD28 and the IL7R-a chain (CD127).
Functional, polyclonal CD4+ and CD8+ WT1- reactive T cells can be efficiently enriched directly ex vivo from the natural repertoire by magnetic separation of T cells after antigen-specific stimulation. Thus, our approach holds great potential for the GMP-compliant generation of WT1-specific T cells for future clinical use.
About this article
Cite this article
Schmied, S., Richter, A. & Assenmacher, M. P66. Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy. j. immunotherapy cancer 2, P40 (2014). https://doi.org/10.1186/2051-1426-2-S2-P40
- Effector Cytokine
- Expansion Protocol
- Efficient Expansion
- Marker CD107a
- Degranulation Marker